
ImmunityBio, Inc.
- Jurisdiction
United States - LEI
529900J9XLBR4HFL4B83 - ISIN
US45256X1037 (IBRX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€48.56M - Gross margin
92.3% - EBIT
-€244.85M - EBIT margin
-504.2% - Net income
-€314.97M - Net margin
-648.6%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Dividends
No dividend payouts